Pfizer has announced it has entered into a second supply agreement which will broaden and extend the duration of the company’s commitment to help protect millions of infants and young children in the developing world from pneumococcal disease – the leading cause of vaccine-preventable death in young children.
Pfizer is now committed to supply up to a total of 480 million doses of Prevenar 13 (Pneumococcal Polysaccharide Conjugate Vaccine through to 2023, building on its original commitment announced in March 2010 to supply up to 300 million doses of the vaccine under the auspices of the Advance Market Commitment (AMC) for pneumococcal vaccines.
The AMC, an innovative programme piloted by the GAVI Alliance, is a public-private approach to health funding designed to create a sustainable marketplace, ensure an affordable and stable supply of pneumococcal vaccines at a steeply discounted price and stimulate the development and expansion of manufacturing capacity for vaccines specifically for the world’s poorest countries. The agreements for supply of pneumococcal vaccines have been financed by GAVI, five donor countries – Italy, the United Kingdom, Canada, the Russian Federation, Norway – and the Bill and Melinda Gates Foundation.
